R. Will

EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma

This study identifies EMP3 as a regulator of EGFR/CDK2 signaling in glioblastoma by stabilizing EGFR and promoting its oncogenic activity.

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

A connectivity signature for glioblastoma

This paper establishes and validates a connectivity signature in glioblastoma using scRNA-Seq data, showing high connectivity correlates with poor patient survival and specific molecular subtypes.

Coordinated regulation of WNT/β-catenin, c-Met, and Integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits

This study identifies miR-193b as a key regulator of WNT/β-catenin, c-Met, and integrin pathways in TNBC, showing its strong repressive effect on metastatic traits.

Reprogramming of stromal fibroblasts by chemotherapy-induced secretion of IFNβ1 drives re-growth of breast cancer cells after treatment.

This study shows chemotherapy-induced IFNβ1 secretion by cancer cells reprograms stromal fibroblasts, promoting breast cancer recurrence through an anti-viral state and pro-inflammatory cytokine expression.

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer

This study identifies ATF3 as a novel mediator of endocrine resistance in breast cancer through time-resolved profiling and validates its role in key signaling pathways and clinical relevance.